MarketPulse

Japan approval

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pharming Charts Growth Despite RUCONEST Decline, Bets on Joenja Expansion

Pharming Group's Q1 2026 revenues fell 8% YoY to $72.4M, hurt by RUCONEST decline, but Joenja surged 34%. Company maintains full-year guidance and advances international launches.
PHAR2026 guidancecash flow positive
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent